Learn how LABD delivers -3x daily biotech exposure, why it’s down 99.98% since inception, and when it fits short-term trades.

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share. But ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast another 150 basis points of rate cuts in 2026. Healthcare stocks trade at some of the ...

Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Faring best of ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Franklin Templeton today announced it will liquidate and dissolve Putnam BioRevolution™ ETF (SYNB). The liquidation is anticipated to occur on or about November 21, ...

Forbes contributors publish independent expert analyses and insights. I'm a journalist who covers finance and investing. Nov 29, 2025, 05:01pm EST Global ETF asset growth as at end of September 2025.

Franklin Templeton today announced it will liquidate and dissolve Putnam BioRevolution™ ETF (SYNB). The liquidation is anticipated to occur on or about November 21, 2025, although the Fund may make ...